These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28710313)

  • 1.
    Chen Y; Xue SA; Behboudi S; Mohammad GH; Pereira SP; Morris EC
    Clin Cancer Res; 2017 Oct; 23(20):6178-6189. PubMed ID: 28710313
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
    J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.
    Osada T; Patel SP; Hammond SA; Osada K; Morse MA; Lyerly HK
    Cancer Immunol Immunother; 2015 Jun; 64(6):677-88. PubMed ID: 25742933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 5. The PD-L1/PD-1 pathway promotes dysfunction, but not "exhaustion", in tumor-responding T cells from pleural effusions in lung cancer patients.
    Prado-Garcia H; Romero-Garcia S; Puerto-Aquino A; Rumbo-Nava U
    Cancer Immunol Immunother; 2017 Jun; 66(6):765-776. PubMed ID: 28289860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements.
    Huarte E; Sarobe P; Lu J; Casares N; Lasarte JJ; Dotor J; Ruiz M; Prieto J; Celis E; Borrás-Cuesta F
    Clin Cancer Res; 2002 Jul; 8(7):2336-44. PubMed ID: 12114438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
    Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of prolactin on carcinoembryonic antigen-specific cytotoxic T lymphocyte response induced by dendritic cells.
    Matera L; Beltramo E; Martinuzzi E; Buttiglieri S
    Clin Exp Immunol; 2004 Aug; 137(2):320-8. PubMed ID: 15270849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
    Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
    Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
    [No Abstract]   [Full Text] [Related]  

  • 11. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection.
    Ferrando-Martinez S; Snell Bennett A; Lino E; Gehring AJ; Feld J; Janssen HLA; Robbins SH
    Front Immunol; 2021; 12():648420. PubMed ID: 34589081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
    Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
    J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
    Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
    Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PD-1/PD-L1 Pathway Affects the Expansion and Function of Cytotoxic CD8
    David P; Megger DA; Kaiser T; Werner T; Liu J; Chen L; Sitek B; Dittmer U; Zelinskyy G
    Front Immunol; 2019; 10():54. PubMed ID: 30804928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppression of Human Adipose-Derived Stem Cells on T Cell Subsets via the Reduction of NF-kappaB Activation Mediated by PD-L1/PD-1 and Gal-9/TIM-3 Pathways.
    Zhou K; Guo S; Tong S; Sun Q; Li F; Zhang X; Qiao Y; Liang G
    Stem Cells Dev; 2018 Sep; 27(17):1191-1202. PubMed ID: 29978730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions.
    Garcia-Bates TM; Palma ML; Shen C; Gambotto A; Macatangay BJC; Ferris RL; Rinaldo CR; Mailliard RB
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
    Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
    Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer.
    Severson JJ; Serracino HS; Mateescu V; Raeburn CD; McIntyre RC; Sams SB; Haugen BR; French JD
    Cancer Immunol Res; 2015 Jun; 3(6):620-30. PubMed ID: 25701326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eligibility of antigenic-peptide-pre-loaded and fixed adhesive peripheral blood cells for induction of cytotoxic T lymphocytes from cancer patients with elevated serum levels of carcinoembryonic antigen.
    Kim CH; Todoroki T; Matsumura M; Ohno T
    J Cancer Res Clin Oncol; 2000 Jul; 126(7):383-90. PubMed ID: 10929760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.